Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE vs FLAGYL I.V. RTU IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Treatment of anaerobic bacterial infections (intra-abdominal, skin and skin structure, gynecologic, bone and joint, central nervous system, lower respiratory tract, endocarditis),Treatment of trichomoniasis (symptomatic and asymptomatic),Treatment of bacterial vaginosis,Treatment of amebiasis (intestinal and hepatic),Prophylaxis of postoperative infection in contaminated or potentially contaminated colorectal surgery,Off-label: Management of Clostridium difficile infection, Helicobacter pylori eradication (part of combination therapy), Crohn's disease (perianal fistulas), rosacea (topical)
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy-metronidazole (active) and acid metabolites. Enzymes: CYP450 (primarily CYP2A6 and CYP3A4).
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
90-95% bound to alpha-1-acid glycoprotein and albumin.
<20%, primarily to albumin.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
0.8-1.2 L/kg; indicates extensive tissue penetration including CNS, bone, and abscesses.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
Oral: 100% (nearly complete absorption).
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No adjustment required for GFR >10 m L/min. For GFR <10 m L/min: administer every 12 hours. Hemodialysis: administer normal dose after dialysis; no supplemental dose needed. Peritoneal dialysis: administer normal dose every 12 hours.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 7.5 mg/kg every 12 hours). Child-Pugh C: use contraindicated or reduce dose to 7.5 mg/kg every 24 hours with close monitoring.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Neonates (0-6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 12 hours. Infants/children (>6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
No specific dose adjustment based solely on age. Monitor renal function and adjust if GFR <10 m L/min. Consider reduced hepatic clearance; use lowest effective dose and monitor for adverse effects.
Not available.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved for conditions described in the indications. Unnecessary use should be avoided.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Carcinogenicity risk (animal data; avoid unnecessary use),Seizures and peripheral neuropathy (discontinue if abnormal neurologic signs occur),Hepatic impairment: dose adjustment may be required; caution in severe liver disease,Renal impairment: accumulation of metabolites; monitor for toxicity,Blood dyscrasias: history of or current; monitor CBC with prolonged therapy,Candidiasis: may cause overgrowth; treat appropriately,Disulfiram-like reaction with alcohol: avoid alcohol during and for 48 hours after therapy,Drug interactions: warfarin (increased INR), lithium (increased toxicity), CYP450 inducers/inhibitors,Pregnancy: reserve for serious infections; use in trichomoniasis only if no alternative,Lactation: discontinue breastfeeding or drug, considering importance to mother
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
Hypersensitivity to metronidazole or other nitroimidazoles,First trimester of pregnancy (for trichomoniasis; relative contraindication),Concurrent use of disulfiram (psychotic reactions possible),Patients with Cockayne syndrome (risk of severe hepatic adverse reactions)
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
No direct food interactions, but alcohol and alcohol-containing foods (e.g., sauces, vinegar, fermented products) must be strictly avoided during therapy and for 48 hours after completion due to risk of disulfiram-like reaction.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: Generally considered safe for short-term treatment of bacterial vaginosis or trichomoniasis; no evidence of increased major malformations. However, use only if clearly needed.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Infant serum levels may be up to 20% of maternal levels. Due to potential carcinogenicity in animal studies and concerns for infant gastrointestinal effects, the manufacturer recommends discontinuing breastfeeding during therapy and for 24-48 hours after last dose. Alternative washing and pumping may be considered.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
Pregnancy may alter metronidazole pharmacokinetics: slightly increased clearance and volume of distribution. No specific dose adjustment is recommended; use standard dosing (e.g., 500 mg IV every 6-8 hours for anaerobic infections). Avoid high doses and prolonged therapy unless essential.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Flagyl IV RTU (metronidazole) is a nitroimidazole antibiotic used for anaerobic infections and protozoal diseases. Avoid alcohol during therapy and for 48 hours after due to disulfiram-like reaction. Infuse slowly over 30-60 minutes to minimize infusion reactions. Monitor for peripheral neuropathy and CNS effects with prolonged use. Use with caution in hepatic impairment; adjust dose in severe liver disease. May cause metallic taste. Do not mix with other drugs in the same IV line. Contraindicated in first trimester of pregnancy unless life-threatening.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
Do not drink alcohol or use products containing alcohol during treatment and for at least 48 hours after the last dose; this can cause severe nausea, vomiting, flushing, and headache.,This medication may cause a metallic taste in the mouth, which is temporary.,If you experience numbness, tingling, or pain in your hands or feet, or any signs of an allergic reaction, contact your healthcare provider immediately.,For IV administration, the infusion site should be monitored for signs of redness, swelling, or pain.,Take the medication exactly as prescribed; do not stop without consulting your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE vs FLAGYL I.V. RTU IN PLASTIC CONTAINER, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. FLAGYL I.V. RTU IN PLASTIC CONTAINER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE and FLAGYL I.V. RTU IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. The standard adult dose of FLAGYL I.V. RTU IN PLASTIC CONTAINER is: Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE and FLAGYL I.V. RTU IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. FLAGYL I.V. RTU IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: General. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.